ACROMETA Signs Sales & Purchase Agreement for Additional 40% of Life Science Incubator
Upon completion of the purchase, the Group will control 70% of LSI, up from the current 30%.
- Upon completion of the purchase, the Group will control 70% of LSI, up from the current 30%.
- The Agreement updates and follows from the Letter of Intent ("LOI") announced to SGXNet on 20 February 2023 for the proposed acquisition of an additional 40% stake in LSI.
- Mr Levin Lee Keng Weng, ACROMETA Chairman, said, "Brisbane is a booming hub for the Life Sciences sector in Australia.
- The proposed additional co-working laboratory space in Singapore is to cater for expected growth in demand.